Europe Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

Europe Peptide Therapeutics Market Size, Share & Industry Trends Analysis Report By Type (Innovative and Generic), By Route of Administration, By Synthesis Technology, By Type of Manufacturers, By Application, By Country and Growth Forecast, 2022 - 2028

The Europe Peptide Therapeutics Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028).

Peptide medications have so many desired qualities, they are transitory in the body due to quick degradation and clearance. Many approaches have been used to boost the stability of peptide therapeutics. Some peptides and proteins have half-lives of only a few minutes, making them inefficient for medication delivery. Peripheral blood-mediated proteolysis, real and hepatic evacuation, and receptor-mediated endocytosis are all mechanisms implicated in their clearance. The molecular weight of the substance is one of the key reasons for its quick clearance.

In Europe, cardiovascular diseases (CVD) continue to be the primary cause of death, accounting for 45% of all deaths in the region, according to the National Library of Medicines. Every year, more than 4 million Europeans die from cardiovascular disease (CVD), mostly coronary heart disease (CHD) and stroke. Many more are admitted to hospitals, and several others acquire long-term disabilities that necessitate lifetime therapies. CVD has huge economic ramifications for Europe, in addition to human misery. CVD is predicted to cost the EU economy €210 billion per year, which includes direct healthcare expenses as well as non-health expenditures such as lost productivity and informal care for people with CVD. The cardiovascular disease mortality rate in Central and Eastern Europe (CEE/CIS) is the highest in the world.

CVD death rates are greater in CEE and CIS, and they occur at younger ages as well. Premature CVD mortality among men in Russia and Belarus (65 years) is more than ten times greater than in Switzerland (300 vs. 26 per 100 000, respectively). Men aged 55–59 years in various CIS nations (Belarus, Kazakhstan, Kyrgyzstan, Russia, and Ukraine) have a higher CVD death rate than men aged 75–79 years in France. When comparing CEE to other European countries, women's premature death patterns are similar to men's, however at lower rates. The requirement for an effective treatment approach for these disorders is at its peak in the region. The adoption of peptide therapeutics is estimated to surge due to this.

The Germany market dominated the Europe Peptide Therapeutics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,458.3 million by 2028. The UK market is estimated to grow at a CAGR of 4.7% during (2022 - 2028). Additionally, The France market would witness a CAGR of 6.3% during (2022 - 2028).

Based on Type, the market is segmented into Innovative and Generic. Based on Route of Administration, the market is segmented into Parenteral Route, Pulmonary, Mucosal, Oral Route, and Others. Based on Synthesis Technology, the market is segmented into Liquid Phase Peptide Synthesis (LPPS), Solid Phase Peptide Synthesis (SPPS), and Hybrid Technology. Based on Type of Manufacturers, the market is segmented into In-house and Outsourced. Based on Application, the market is segmented into Metabolic, Cardiovascular Disorder, GIT & Renal, Antiinfection & Dermatology, Respiratory, Central Nervous System, Cancer, Pain, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Lonza Group AG, and Amgen, Inc.

Scope of the Study

Market Segments covered in the Report:

By Type

  • Innovative
  • Generic
By Route of Administration
  • Parenteral Route
  • Pulmonary
  • Mucosal
  • Oral Route
  • Others
By Synthesis Technology
  • Liquid Phase Peptide Synthesis (LPPS)
  • Solid Phase Peptide Synthesis (SPPS)
  • Hybrid Technology
By Type of Manufacturers
  • In-house
  • Outsourced
By Application
  • Metabolic
  • Cardiovascular Disorder
  • GIT & Renal
  • Antiinfection & Dermatology
  • Respiratory
  • Central Nervous System
  • Cancer
  • Pain
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Eli Lilly And Company
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • GlaxoSmithKline PLC
  • Takeda Pharmaceutical Company Limited
  • Lonza Group AG
  • Amgen, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.1 Objectives
1.2 Market Scope
1.3 Segmentation
1.3.1 Europe Peptide Therapeutics Market, by Type
1.3.2 Europe Peptide Therapeutics Market, by Route of Administration
1.3.3 Europe Peptide Therapeutics Market, by Synthesis Technology
1.3.4 Europe Peptide Therapeutics Market, by Type of Manufacturers
1.3.5 Europe Peptide Therapeutics Market, by Application
1.3.6 Europe Peptide Therapeutics Market, by Country
1.4 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trails
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
Chapter 4. Europe Peptide Therapeutics Market by Type
4.1 Europe Innovative Market by Country
4.2 Europe Generic Market by Country
Chapter 5. Europe Peptide Therapeutics Market by Route of Administration
5.1 Europe Parenteral Route Market by Country
5.2 Europe Pulmonary Market by Country
5.3 Europe Mucosal Market by Country
5.4 Europe Oral Route Market by Country
5.5 Europe Others Market by Country
Chapter 6. Europe Peptide Therapeutics Market by Synthesis Technology
6.1 Europe Liquid Phase Peptide Synthesis (LPPS) Market by Country
6.2 Europe Solid Phase Peptide Synthesis (SPPS) Market by Country
6.3 Europe Hybrid Technology Market by Country
Chapter 7. Europe Peptide Therapeutics Market by Type of Manufacturers
7.1 Europe In-house Market by Country
7.2 Europe Outsourced Market by Country
Chapter 8. Europe Peptide Therapeutics Market by Application
8.1 Europe Metabolic Market by Country
8.2 Europe Cardiovascular Disorder Market by Country
8.3 Europe GIT & Renal Market by Country
8.4 Europe Antiinfection & Dermatology Market by Country
8.5 Europe Respiratory Market by Country
8.6 Europe Central Nervous System Market by Country
8.7 Europe Cancer Market by Country
8.8 Europe Pain Market by Country
8.9 Europe Others Market by Country
Chapter 9. Europe Peptide Therapeutics Market by Country
9.1 Germany Peptide Therapeutics Market
9.1.1 Germany Peptide Therapeutics Market by Type
9.1.2 Germany Peptide Therapeutics Market by Route of Administration
9.1.3 Germany Peptide Therapeutics Market by Synthesis Technology
9.1.4 Germany Peptide Therapeutics Market by Type of Manufacturers
9.1.5 Germany Peptide Therapeutics Market by Application
9.2 UK Peptide Therapeutics Market
9.2.1 UK Peptide Therapeutics Market by Type
9.2.2 UK Peptide Therapeutics Market by Route of Administration
9.2.3 UK Peptide Therapeutics Market by Synthesis Technology
9.2.4 UK Peptide Therapeutics Market by Type of Manufacturers
9.2.5 UK Peptide Therapeutics Market by Application
9.3 France Peptide Therapeutics Market
9.3.1 France Peptide Therapeutics Market by Type
9.3.2 France Peptide Therapeutics Market by Route of Administration
9.3.3 France Peptide Therapeutics Market by Synthesis Technology
9.3.4 France Peptide Therapeutics Market by Type of Manufacturers
9.3.5 France Peptide Therapeutics Market by Application
9.4 Russia Peptide Therapeutics Market
9.4.1 Russia Peptide Therapeutics Market by Type
9.4.2 Russia Peptide Therapeutics Market by Route of Administration
9.4.3 Russia Peptide Therapeutics Market by Synthesis Technology
9.4.4 Russia Peptide Therapeutics Market by Type of Manufacturers
9.4.5 Russia Peptide Therapeutics Market by Application
9.5 Spain Peptide Therapeutics Market
9.5.1 Spain Peptide Therapeutics Market by Type
9.5.2 Spain Peptide Therapeutics Market by Route of Administration
9.5.3 Spain Peptide Therapeutics Market by Synthesis Technology
9.5.4 Spain Peptide Therapeutics Market by Type of Manufacturers
9.5.5 Spain Peptide Therapeutics Market by Application
9.6 Italy Peptide Therapeutics Market
9.6.1 Italy Peptide Therapeutics Market by Type
9.6.2 Italy Peptide Therapeutics Market by Route of Administration
9.6.3 Italy Peptide Therapeutics Market by Synthesis Technology
9.6.4 Italy Peptide Therapeutics Market by Type of Manufacturers
9.6.5 Italy Peptide Therapeutics Market by Application
9.7 Rest of Europe Peptide Therapeutics Market
9.7.1 Rest of Europe Peptide Therapeutics Market by Type
9.7.2 Rest of Europe Peptide Therapeutics Market by Route of Administration
9.7.3 Rest of Europe Peptide Therapeutics Market by Synthesis Technology
9.7.4 Rest of Europe Peptide Therapeutics Market by Type of Manufacturers
9.7.5 Rest of Europe Peptide Therapeutics Market by Application
Chapter 10. Company Profiles
10.1 Eli Lilly And Company
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.1.5.2 Acquisition and Mergers:
10.1.5.3 Approvals and Trails:
10.2 AstraZeneca PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development Expenses
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.2.5.2 Acquisition and Mergers:
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expenses
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals and Acquisitions:
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Acquisition and Mergers:
10.4.5.2 Approvals and Trails:
10.5 Pfizer, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional & Segmental Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Acquisition and Mergers:
10.6 Sanofi S.A.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expense
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 GlaxoSmithKline PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expense
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expense
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals and Trails:
10.9 Lonza Group AG
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Segmental and Regional Analysis
10.9.4 Research & Development Expenses
10.10. Amgen, Inc.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Partnerships, Collaborations, and Agreements:

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings